Cargando…
Anti-S1 MERS-COV IgY Specific Antibodies Decreases Lung Inflammation and Viral Antigen Positive Cells in the Human Transgenic Mouse Model
The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 and causes severe and often fatal acute respiratory illness in humans. No approved prophylactic and therapeutic interventions are currently available. In this study, we have developed egg yolk antibodies (immunoglobul...
Autores principales: | Abbas, Aymn T., El-Kafrawy, Sherif A., Sohrab, Sayed Sartaj, Tabll, Ashraf A., Hassan, Ahmed M., Iwata-Yoshikawa, Naoko, Nagata, Noriyo, Azhar, Esam I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712919/ https://www.ncbi.nlm.nih.gov/pubmed/33139631 http://dx.doi.org/10.3390/vaccines8040634 |
Ejemplares similares
-
Immunotherapeutic Efficacy of IgY Antibodies Targeting the Full-Length Spike Protein in an Animal Model of Middle East Respiratory Syndrome Coronavirus Infection
por: El-Kafrawy, Sherif A., et al.
Publicado: (2021) -
IgY antibodies for the immunoprophylaxis and therapy of respiratory infections
por: Abbas, Aymn Talat, et al.
Publicado: (2018) -
IgY antibodies: The promising potential to overcome antibiotic resistance
por: El-Kafrawy, Sherif A., et al.
Publicado: (2023) -
Designing and evaluation of MERS-CoV siRNAs in HEK-293 cell line
por: Sohrab, Sayed Sartaj, et al.
Publicado: (2021) -
In Vitro Inhibitory Analysis of Rationally Designed siRNAs against MERS-CoV Replication in Huh7 Cells
por: El-Kafrawy, Sherif Aly, et al.
Publicado: (2021)